|
CUSIP No. 92941V100
|
SCHEDULE
13G/A
|
Page 4 of 9 Pages
|
|
|
|
|
|
|
|
1
|
NAME OF REPORTING PERSONS
Mr. Ortav
Yehudai
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
o
(b)
o
|
|
|
3
|
SEC
USE ONLY
|
|
4
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE
VOTING POWER
0
|
|
6
|
SHARED
VOTING POWER
0
|
|
7
|
SOLE
DISPOSITIVE POWER
0
|
|
8
|
SHARED
DISPOSITIVE POWER
0
|
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
|
10
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES
|
o
|
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.0%
|
|
12
|
TYPE
OF REPORTING PERSON
IN/HC
|
|
CUSIP No. 92941V100
|
SCHEDULE
13G/A
|
Page 5 of 9 Pages
|
| Item 1. |
|
(a) Name of Issuer |
VYNE Therapeutics Inc.
| Item 1. |
|
(b) Address of Issuer’s Principal
Executive Offices |
520 U.S. Highway 22, Suite
204
Bridgewater, New Jersey
08807
| Item 2. |
|
(a) Names of Persons
Filing: |
Great Point Partners, LLC
Dr. Jeffrey R. Jay, M.D.
Mr. Ortav Yehudai
The Reporting Persons have entered
into a Joint Filing Agreement, dated February 16, 2021, a copy of
which is filed with this Schedule 13G/A as Exhibit A, pursuant to
which the Reporting Persons have agreed to file this statement
jointly in accordance with the provisions of Rule 13d-1(k)(1) under
the Act.
| Item 2. |
|
(b) Address of Principal Business
Office: |
The address of the principal business
office of each of the Reporting Persons is
165 Mason Street, 3rd
Floor
Greenwich, CT 06830
Great Point Partners, LLC is a
limited liability company organized under the laws of the State of
Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United
States. Mr. Ortav Yehudai is a citizen of the United
States.
| Item 2. |
|
(d) Title of Class of
Securities |
Common Stock, par value $0.0001 per
share
92941V100
|
CUSIP No. 92941V100
|
SCHEDULE
13G/A
|
Page 6 of 9 Pages
|
| |
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
|
| |
(a) |
¨ |
Broker or dealer registered under section 15 of the Act (15
U.S.C. 78o); |
| |
| |
(b) |
¨ |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C.
78c); |
| |
| |
(c) |
¨ |
Insurance company as defined in section 3(a)(19) of the Act (15
U.S.C. 78c); |
| |
| |
(d) |
¨ |
Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8); |
| |
| |
(e) |
o |
An investment adviser in accordance with
§240.13d-1(b)(1)(ii)(E); |
| |
| |
(f) |
¨ |
An employee benefit plan or endowment fund in accordance with
§240.13d-1(b)(1)(ii)(F); |
| |
| |
(g) |
¨ |
A parent holding company or control person in accordance with
§240.13d-1(b)(1)(ii)(G); |
| |
| |
(h) |
¨ |
A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813); |
| |
| |
(i) |
¨ |
A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3); |
| |
| |
(j) |
¨ |
A non-U.S. institution in accordance with
§240.13d-1(b)(1)(ii)(J); |
|
| |
| |
(k) |
¨ |
A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing
as a non-U.S. institution in accordance with
§240.13d-1(b)(1)(ii)(J), please specify the type of
institution: |
| |
|
|
|
|
CUSIP No. 92941V100
|
SCHEDULE
13G/A
|
Page 7 of 9 Pages
|
Item
4. Ownership
1. Great Point Partners,
LLC
(a) Amount beneficially owned:
0
(b) Percent of class:
0.0%
(c) Number of shares as to which the
person has:
(i) Sole power to vote or direct the
vote: 0
(ii) Shared power to vote or direct
the vote: 0
(iii) Sole power to dispose or to
direct the disposition of: 0
(iv) Shared power to dispose or to
direct the disposition of: 0
2. Dr. Jeffrey R. Jay,
M.D.
(a) Amount beneficially owned:
0
(b) Percent of class:
0.0%
(c) Number of shares as to which the
person has:
(i) Sole power to vote or direct the
vote: 0
(ii) Shared power to vote or direct
the vote: 0
(iii) Sole power to dispose or to
direct the disposition of: 0
(iv) Shared power to dispose or to
direct the disposition of: 0
3. Mr. Ortav
Yehudai
(a) Amount beneficially owned:
0
(b) Percent of class:
0.0%
(c) Number of shares as to which the
person has:
(i) Sole power to vote or direct the
vote: 0
(ii) Shared power to vote or direct
the vote: 0
(iii) Sole power to dispose or to
direct the disposition of: 0
(iv) Shared power to dispose or to
direct the disposition of: 0
Item 5. Ownership of Five Percent or
Less of a Class
If this statement is being filed to
report the fact that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five percent of the
class of securities, check the following [X].
Item 6. Ownership of More Than Five
Percent on Behalf of Another Person
See Item 4.
Item 7. Identification and
Classification of the Subsidiary which Acquired the Security Being
Reported on by the Parent Holding Company or Control
Person
Not Applicable.
Item 8. Identification and
Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of
Group
Not Applicable.
Item 10.
Certification
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or
effect.
|
CUSIP No. 92941V100
|
SCHEDULE
13G/A
|
Page 8 of 9 Pages
|
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set
forth in this statement is true, complete and
correct.
Dated: February 16,
2021
|
| |
Great
Point Partners, LLC
|
| |
|
|
|
| |
By: |
/s/
Dr. Jeffrey R. Jay, M.D. |
| |
|
Dr.
Jeffrey R. Jay, M.D., as Senior Managing Member |
| |
|
|
|
| |
Dr.
Jeffrey R. Jay, M.D.
|
| |
|
|
|
| |
By: |
/s/
Dr. Jeffrey R. Jay, M.D. |
| |
|
Dr.
Jeffrey R. Jay, M.D. |
|
|
| |
|
|
|
| |
Mr.
Ortav Yehudai
|
| |
|
|
|
| |
By: |
/s/
Mr. Ortav Yehudai |
| |
|
Mr.
Ortav Yehudai |
| |
|
|
|
